Navin Fluorine — the margin guidance that couldn’t keep up

The State of Play

Navin Fluorine spent FY26 doing something unusual on Indian earnings calls: repeatedly raising its margin guidance and still getting beaten by its own results. The 25% EBITDA target set in May 2025 became “north of 25%” in July, “28 to 30%” in October, and by February the CFO simply conceded: “it is now safe to think of Navin as a 30% annual number.” The year closed (per the screener tables; the Q4 call transcript wasn’t available) at ₹3,314 crore of revenue, up 41%, with a 33% operating margin and net profit of ₹664 crore — more than double the prior year. The engine: a refrigerant-gas supercycle in R32, a specialty-chemicals plant hitting stride, and a CDMO business growing toward its $100 million aspiration.

The Company

Part of the Padmanabh Mafatlal group and in fluorine chemistry since 1967, Navin runs three reporting verticals. HPP (high-performance products) is the legacy core — refrigerant gases, especially R32, plus inorganic fluorides and now a 40,000-tonne anhydrous HF “mother plant” that feeds everything downstream. Specialty chemicals makes complex fluorinated intermediates for global agrochemical innovators — the ₹540 crore “Nectar” fluoro-specialty plant at Dahej, commissioned December 2024, anchors it. CDMO (Navin Molecular) does contract development and manufacturing for pharma — its flagship relationship is with Finland’s Fermion, with a dedicated cGMP-4 plant. A fourth leg, advanced materials, is being incubated: a deal with Chemours to manufacture Opteon two-phase immersion-cooling fluid for AI data centers (operational Q1 FY27), electronic-grade HF with Swiss partner BUSS ChemTech, and semiconductor-gas ambitions.

Chairman Vishad Mafatlal is a second-generation promoter; promoters hold 27.1%, trimmed gently from 28.8% over two years while FIIs climbed from 18% to 23.8% — institutions now own over half the company. The structural story under the P&L is a heavy capex cycle: fixed assets grew from ~₹556 crore (FY22) to ₹3,324 crore (FY26), funded by debt that peaked near ₹1,466 crore before a ₹750 crore QIP in July 2025 took net debt-to-equity to 0.03x by December. The annual reports record the rough patch this cycle bridged: FY24 revenue actually fell 13% standalone on weak exports, before the new assets started paying.

The Story So Far

Q4 FY25 (call: May 9, 2025) — the setup quarter

FY25 closed at ₹2,349 crore (+14%) with a 22.7% operating EBITDA margin, and the March quarter — ₹701 crore, 25.5% margin — was the first proof the margin reset was real. The R32 second plant had been commercialised in March 2025 and was already at optimal capacity. Management set the year’s terms: FY26 EBITDA margin “reset to 25%” (range 23–27%), the AHF plant done by Q2 FY26, cGMP-4 Phase 1 by end-Q3, and the newly announced Chemours Opteon facility — a $14 million plant, $5 million funded by Chemours itself — by Q1 FY27. The CDMO’s $100 million FY27 aspiration was reaffirmed with unusual candour about its arithmetic: one-third from the known Fermion contract, one-third from a new MSA, one-third from base business. “Even if we are 90, it doesn’t change the dial” — Anish Ganatra, CFO.

Q1 FY26 (call: July 30, 2025) — the beat begins

June-quarter revenue rose 39% to ₹725 crore and the EBITDA margin printed 28.5% — 935 basis points above the prior year, two-thirds of the bridge from operating leverage, one-third from pricing, “a lot of that… from the strong R32 refrigerant gas pricing environment.” Asked to raise the 25% guidance, the CFO declined with a phrase that set the year’s pattern: “Let this cement for a couple of quarters and then we can revisit.” The ₹750 crore QIP closed the same month, and the capex frame widened from ₹500–600 crore to ₹700–1,000 crore a year. The most strategically loaded exchange: an analyst computed Navin’s R32 quota entitlement under the Kigali rules at ~26,000–27,000 tonnes against ~10,000 tonnes of capacity — would Navin stake the full claim? “The answer is a simple yes. The question is when.”

Q2 FY26 (call: October 30, 2025) — the quota gets its capex

September-quarter revenue rose 46% to ₹758 crore at a 32.5% margin; every segment fired — HPP crossed ₹400 crore, specialty rose 39%, CDMO doubled. The guidance moved: “well on track to be between 28% to 30% for the year.” And the R32 answer arrived as money: a ₹236.5 crore project for up to 15,000 MTPA of additional R32 (peak revenue ₹600–825 crore a year), plus ₹75 crore of specialty debottlenecking (peak ₹140–160 crore), both internally funded, both due Q3 FY27. The logic management laid out is the closest thing the stock has to a thesis: world ex-China R32 demand grows ~5% a year, China’s capacity stays home, Western capacity is being cut, India cannot add new capacity after 2026 — so “additional supply can only come from India,” and Navin holds entitlement. Contracts run 4–5 years, priced near market. Meanwhile AHF slipped a quarter (now Q3 FY26, mechanical trials underway), and Fermion’s cGMP-4 supplies were set for January 2026.

Q3 FY26 (call: February 9, 2026) — “safe to think of Navin as a 30% company”

The December quarter was the year’s exclamation mark: revenue ₹892 crore (+47%), EBITDA margin 34.5%, PAT ₹185 crore. Nine-month PAT of ₹451 crore had already beaten the whole of FY25’s ₹289 crore. Specialty posted its highest-ever quarter (₹354 crore, +60%) — pointedly, while the rest of the agchem industry sat in a downcycle, which management attributed to its shift from transactional supplier to “technology partner”: “lift, shift, adapt, embed.” CDMO grew 61%, with Fermion’s commercial supplies from cGMP-4 begun on schedule and “revenue visibility over the next three years.” AHF was finally commissioned — in Q4 FY26, two quarters past the original promise, the year’s only notable slippage. The guidance ladder reached its top rung:

“It is now safe to think of Navin as a 30% annual number… give or take plus/minus 200 basis points.” — Anish Ganatra, Q3 FY26 call

Net debt-to-equity stood at 0.03x and working capital below 80 days of sales. The watch-items management itself named: rising sulfur and fluorspar input costs, and structurally permanent agchem pricing pressure.

Q4 FY26 — the scoreboard (from the financials)

The March-2026 quarter, per the screener tables, delivered ₹938 crore of sales at a 34% operating margin and ₹213 crore of net profit — records on every line. The full year: ₹3,314 crore of revenue (+41%), operating profit of ₹1,082 crore (+103%), a 33% operating margin against the original “25%, range 23–27%” guidance, and EPS of ₹129 versus ₹58 a year earlier.

The ledger: said vs. delivered

Beaten: every version of the margin guidance — 25% guided, 33% delivered, with the guidance trailing the results all year rather than leading them. Kept: cGMP-4 Phase 1 on its Q3 FY26 timeline with Fermion supplies starting January 2026 as promised; the Chemours Q1 FY27 date held across all four calls; R32 at 100% utilisation throughout; the new-molecule cadence in specialty (three molecules promised in August, supplies begun on schedule); working-capital and leverage discipline better than promised. Slipped: AHF, the one persistent laggard — Q2 FY26 became Q3 became “commissioned in Q4,” two quarters late. Still open: the $100 million CDMO aspiration (FY27 — the year now underway); full Nectar PAR by end-FY27; the Wave-2 projects (15,000 MTPA R32 and MPP debottlenecking) due Q3 FY27; and the full R32 quota build-out beyond that. The honest caveat embedded in the 30% guidance: it leans on an R32 price environment management itself calls “constructive” — a regulatory-scarcity tailwind, not a permanent fact.

Where Things Stand

Navin enters FY27 with all three verticals compounding, a near-degeared balance sheet, ₹600–700 crore of annual capex flowing into projects with named peak revenues, and the data-center-adjacent advanced-materials bets (Chemours Opteon, electronic-grade HF, BF₃) approaching first commercial production. The checkable FY27 list: Chemours operational by Q1, R32 expansion and MPP debottlenecking by Q3, cGMP-4 at full utilisation, Nectar’s second half secured, the $100 million CDMO mark, and one or two new agchem molecules a quarter. The risks are the mirror of the strengths: R32 pricing (the single biggest margin contributor), sulfur and fluorspar costs, structural agchem price pressure — and a valuation (P/E ~54, 9x book) that, as with everything in this sector right now, pays today for the 30%-margin company management only recently admitted it had become.

The Four Checks

1. Quality and moat. A good business with a layered, partial moat. The durable part is fluorine chemistry itself — six decades of handling a dangerous element, 60+ compounds, and customer qualification that turns agchem and CDMO relationships sticky (Fermion’s dedicated cGMP-4 plant, the “lift, shift, adapt, embed” shift from supplier to technology partner — visible in specialty growing 60% while the rest of agchem sat in a downcycle). The second layer is regulatory: the Kigali quota gives Navin entitlement to ~26,000–27,000 tonnes of R32 against ~10,000 tonnes of capacity, in a world where India cannot add new capacity after 2026 and China’s stays home. But the biggest current profit pool — refrigerant gas — is priced by a cycle management itself calls merely “constructive,” and agchem pricing pressure is, in their own words, structurally permanent. Call it a decent moat in specialty and CDMO wrapped around a commodity-cyclical core with a regulatory scarcity bonus.

2. Returns on incremental capital and runway. The capex cycle is the test, and so far it passes: fixed assets went from ~₹556 crore (FY22) to ₹3,324 crore (FY26), and the snapshot now shows ROCE of 21.4% and ROE of 20.3% — recovered from the FY24 trough when revenue fell and margins hit 19%. FY26’s doubling of operating profit on 41% revenue growth says the new assets (R32 plant two, Nectar, cGMP-4, AHF) are earning well above cost of capital. The runway is unusually legible — named projects with named peak revenues (₹236.5 crore for 15,000 MTPA of R32 with ₹600–825 crore peak revenue, ₹75 crore of debottlenecking for ₹140–160 crore), plus the $100 million CDMO mark and the advanced-materials bets. The caveat: a meaningful slice of the FY26 return jump is R32 pricing, not just volume, so the through-cycle incremental return is likely high-teens rather than the headline.

3. Capital allocation for the stage. Broadly textbook for a build phase, judged by actions. Management is reinvesting hard while returns are high — ₹700–1,000 crore of annual capex, Wave-2 projects internally funded — and keeping the dividend token (12% payout in FY25 and FY26) rather than pretending to be a yield stock mid-cycle. The ₹750 crore QIP of July 2025 diluted shareholders, but at ~50x earnings it was cheap equity that took net debt-to-equity to 0.03x; selling stock when it’s expensive is the mirror image of buying it back when it’s cheap. No buyback history is visible in the data, and none would make sense at 9x book. The quibbles: promoters have trimmed from 28.8% to 27.1% into the run-up, and screener flags working-capital days at 178 against management’s claimed sub-80 days of sales — both worth watching, neither yet a sin.

4. Price. Demanding. As of the June 2026 snapshot the stock trades at ₹7,053 — a ₹36,171 crore market cap, 54 times earnings and 9 times book — on a year in which the operating margin printed 33% against the 23% of FY25 and the 19% of FY24. The market is paying a premium multiple on cyclically elevated earnings: the single biggest margin contributor is an R32 price environment that is a regulatory-scarcity tailwind, not a permanent fact, and management’s own watch-items (sulfur, fluorspar, structural agchem pricing) all push the other way. If the 30%-margin company proves durable and the FY27 project list lands on time, the price is merely full; if R32 normalises, there is a long way down to a fair multiple. Either way, today’s buyer is paying for everything to keep going right.

Sources

• Concall transcripts (4): Q4 FY25 (May 9, 2025), Q1 FY26 (Jul 30, 2025), Q2 FY26 (Oct 30, 2025), Q3 FY26 (Feb 9, 2026) — BSE filings, converted to markdown. The Q4 FY26 (May 2026) transcript was not retrievable (the screener link served a web page, not a PDF) — Q4 outcomes above are taken from the screener financial tables instead.
• Annual reports (3): FY23, FY24, FY25 sections — thin on narrative; main contributions were the FY24 export-led revenue decline (the trough this cycle climbed out of) and capex trajectories.
• Screener.in snapshot: consolidated quarterly and annual tables, ratios, shareholding — fetched 2026-06-05 (logged-out session).
• Research files: vault/Sources/Earnings/Navin Fluorine International Ltd/ — raw transcripts, AR sections, snapshot, per-document digests (not published).